

Resources and tools for guideline developers, health technology assessment teams and decision makers interested in rapid guidance or HTA products

**DRAFT of sections to cover**

*Prepared by the COVID-END Recommending Working Group*

*1. Definition of Guidelines*

- *(to provide accepted definition of CPGs and differentiate them from consensus documents)*
- *Provide definitions of HTA, economic analyses, etc*
- *Also provide definitions on rapid, emergent guidance, etc.*
- *Also, provide definitions of Health systems guidance and public health guidelines.*

*2. Importance of Guidelines /guidance in COVID 19*

- *Brief summary of the impact of CPGs/HTA on emergencies (why they are desirable over other documents)*

*3. Determining the need for developing guideline/guidance on COVID 19*

- *This is about some criteria for starting a new CPG/HTA development process, or considering adaptation (new evidence, a new CPG, clinical variability, etc.)*
- *Adding here a flow chart of development/adaptation*

*4. Gathering the best guideline/HTA team*

- *Recommendations for potential users about how a guideline team should be composed*
- *Recommendations for potential users about how an HTA team should be composed*

*5. Types and models for guidance /guidelines and HTA development and deciding on the best approach for obtaining guidance and recommendations*

- *Provide definitions and resources that support them: De novo development, adaptation, adoption/endorsement (CPGs) [something similar for HTA?]*
- *Provide guidance on the best model for each user considering costs, time, evidence, organization constraints, capacity, etc.*

*6. Technology-based models and resources to support Guidelines development and updating*

- *E.g., MAGIC, GRADE Pro*

*7. Tools needed in the CPG/HTA development for assessing the quality of the available guidelines*

- *Information on tools and frameworks useful for assessing, and developing Guidelines*
  - i. Assessing the quality of CPGs (AGREE)*
  - ii. Reporting checklists (e.g., RIGHT)*
  - iii. Developing the guideline and assessing the quality of the evidence (e.g., GRADE), 4. Moving from evidence to recommendation (e.g., EtD)*
  - iv. Resources for HTA?/ Economic analysis (e.g., CHEERS)*
- 8. *Sources for primary studies and secondary studies (evidence synthesis)*
  - *Perhaps linking to the Synthesis group document*
- 9. *Sources for available CPGs*
  - *CPGs: Provide well known databases and platforms (e.g., ECRI, PubMed, Guideline Central, trip database)*
  - *HTA: INAHTA, CRD, NHS EED, EconLit, etc.*
- 10. *How to incorporate economic analysis/HTA in CPG development*
  - *I thought about some guidance (a paragraph?) on how to use economic evidence in the CPG development \*resources,*